Clin Endosc.  2022 Nov;55(6):726-735. 10.5946/ce.2022.132.

Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease

Affiliations
  • 1Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
  • 2Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Abstract

Inflammatory bowel disease (IBD) has a global presence with rapidly increasing incidence and prevalence. Patients with IBD including those with ulcerative colitis and Crohn’s disease have a higher risk of developing colorectal cancer (CRC) compared to the general population. Risk factors for CRC in patients with IBD include long disease duration, extensive colitis, primary sclerosing cholangitis, family history of CRC, stricture, and prior dysplasia. Surveillance colonoscopy for CRC in patients with IBD should be tailored to individualized risk factors and requires careful monitoring every year to every five years. The current surveillance techniques are based on several guidelines. Chromoendoscopy with targeted biopsy is being recommended increasingly, and high-definition colonoscopy is gradually replacing standard-definition colonoscopy. However, it remains unclear whether chromoendoscopy, virtual chromoendoscopy, or white-light endoscopy has better efficiency when a high-definition scope is used. With the development of new endoscopic instruments and techniques, the paradigm of surveillance strategy has gradually changed. In this review, we discuss cutting-edge surveillance colonoscopy in patients with IBD including a review of literature.

Keyword

Colitis-associated dysplasia; Colitis, ulcerative; Crohn disease; Inflammatory bowel diseases; Surveillance

Figure

  • Fig. 1. Endoscopic images of non-polypoid dysplasia. (A) Standard-definition white-light endoscopy. (B) High-definition white-light endoscopy. (C) High-definition narrow-band imaging. (D) Standard-definition chromoendoscopy using indigo carmine at a low concentration (0.04%). (E) Standard-definition chromoendoscopy using indigo carmine at a high concentration (0.2%).

  • Fig. 2. Forest plot for randomized controlled trials comparing high-definition chromoendoscopy and high-definition white-light endoscopy. HD, high-definition; CE, chromoendoscopy; WLE, white-light endoscopy; M-H, Mantel-Haenszel; CI, confidence interval.

  • Fig. 3. Proposed positioning of techniques for surveillance colonoscopy in patients with inflammatory bowel disease. CE, chromoendoscopy; HD, high-definition; SD, standard-definition; WLE, white-light endoscopy; VCE, virtual CE. a)Risk factors for the high-risk group include primary sclerosing cholangitis, history of dysplasia, and chronic or severe inflammatory features such as post-inflammatory polyps, stricture, and tubular/shortened bowel.


Reference

1. Crohn B. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925; 170:220–228.
Article
2. Goldgraber MB, Kirsner JB. Carcinoma of the colon in ulcerative colitis. Cancer. 1964; 17:657–665.
Article
3. Kim KT, Lee HJ, Kang SW, et al. Malignant change of chronic ulcerative colitis: report of a case. J Korean Radiol Soc. 1988; 24:1103–1106.
Article
4. Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006; 63:558–565.
Article
5. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48:526–535.
Article
6. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004; 2:1088–1095.
Article
7. Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143:375–381.
Article
8. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013; 19:789–799.
9. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009; 136:1561–1567.
Article
10. Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012; 57:503–507.
Article
11. Wei SC, Shieh MJ, Chang MC, et al. Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc. 2012; 75:151–155.
Article
12. Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer. 2003; 89:1232–1236.
Article
13. Lee HS, Park SH, Yang SK, et al. The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol. 2015; 50:188–196.
Article
14. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020; 395:123–131.
Article
15. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020; 5:475–484.
Article
16. Bye WA, Ma C, Nguyen TM, et al. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a Cochrane systematic review and meta-analysis. Am J Gastroenterol. 2018; 113:1801–1809.
Article
17. Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015; 110:1022–1034.
Article
18. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006; 12:205–211.
Article
19. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145:166–175.
Article
20. Wijnands AM, de Jong ME, Lutgens MW, et al. Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. Gastroenterology. 2021; 160:1584–1598.
Article
21. Choi CR, Al Bakir I, Ding NJ, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2019; 68:414–422.
Article
22. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008; 57:1246–1251.
Article
23. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003; 124:544–560.
Article
24. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019; 13:144–164.
Article
25. Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1–s106.
Article
26. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019; 114:384–413.
Article
27. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018; 113:481–517.
Article
28. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021; 161:1043–1051.
Article
29. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015; 81:489–501.
Article
30. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124:880–888.
Article
31. Feuerstein JD, Rakowsky S, Sattler L, et al. Meta-analysis of dye-based chromoendoscopy compared with standard-and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019; 90:186–195.
32. Subramanian V, Ramappa V, Telakis E, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:350–355.
Article
33. Buchner AM, Shahid MW, Heckman MG, et al. High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol. 2010; 8:364–370.
Article
34. Wan J, Zhang Q, Liang SH, et al. Chromoendoscopy with targeted biopsies is superior to white-light endoscopy for the long-term follow-up detection of dysplasia in ulcerative colitis patients: a multicenter randomized-controlled trial. Gastroenterol Rep (Oxf). 2020; 9:14–21.
Article
35. Iacucci M, Kaplan GG, Panaccione R, et al. A randomized trial comparing high definition colonoscopy alone with high definition dye spraying and electronic virtual chromoendoscopy for detection of colonic neoplastic lesions during IBD surveillance colonoscopy. Am J Gastroenterol. 2018; 113:225–234.
Article
36. Alexandersson B, Hamad Y, Andreasson A, et al. High-definition chromoendoscopy superior to high-definition white-light endoscopy in surveillance of inflammatory bowel diseases in a randomized trial. Clin Gastroenterol Hepatol. 2020; 18:2101–2107.
Article
37. Yang DH, Park SJ, Kim HS, et al. High-definition chromoendoscopy versus high-definition white light colonoscopy for neoplasia surveillance in ulcerative colitis: a randomized controlled trial. Am J Gastroenterol. 2019; 114:1642–1648.
Article
38. Pellisé M, López-Cerón M, Rodríguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc. 2011; 74:840–848.
Article
39. Efthymiou M, Allen PB, Taylor AC, et al. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:2132–2138.
Article
40. Bisschops R, Bessissow T, Joseph JA, et al. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. Gut. 2018; 67:1087–1094.
Article
41. Resende RH, Ribeiro IB, de Moura DT, et al. Surveillance in inflammatory bowel disease: is chromoendoscopy the only way to go? A systematic review and meta-analysis of randomized clinical trials. Endosc Int Open. 2020; 8:E578–E590.
Article
42. Kandiah K, Subramaniam S, Thayalasekaran S, et al. Multicentre randomized controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). Gut. 2021; 70:1684–1690.
Article
43. González-Bernardo O, Riestra S, Vivas S, et al. Chromoendoscopy with indigo carmine vs virtual chromoendoscopy (iSCAN 1) for neoplasia screening in patients with inflammatory bowel disease: a prospective randomized study. Inflamm Bowel Dis. 2021; 27:1256–1262.
Article
44. Gulati S, Dubois P, Carter B, et al. A randomized crossover trial of conventional vs virtual chromoendoscopy for colitis surveillance: dysplasia detection, feasibility, and patient acceptability (CONVINCE). Inflamm Bowel Dis. 2019; 25:1096–1106.
Article
45. Soetikno R, Subramanian V, Kaltenbach T, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013; 144:1349–1352.
Article
46. Moussata D, Allez M, Cazals-Hatem D, et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut. 2018; 67:616–624.
Article
47. Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology. 2016; 151:1122–1130.
Article
48. Rabinowitz LG, Kumta NA, Marion JF. Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. Gastrointest Endosc. 2022; 95:30–37.
Article
49. Kiesslich R. SCENIC update 2021: is chromoendoscopy still standard of care for inflammatory bowel disease surveillance? Gastrointest Endosc. 2022; 95:38–41.
Article
50. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Incidence of interval colorectal cancer among inflammatory bowel disease patients undergoing regular colonoscopic surveillance. Clin Gastroenterol Hepatol. 2015; 13:1656–1661.
Article
51. Wintjens DS, Bogie RM, van den Heuvel TR, et al. Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: a Dutch population-based cohort study. J Crohns Colitis. 2018; 12:777–783.
Article
Full Text Links
  • CE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr